WAVE LIFE SCIENCES LTD.
Last · NasdaqGM$3.28-0.18 (-5.20%)stale · yahoo · 52h ago
Market cap$646.32M197.0M sh
P/E · TTM-3.2fwd -2.8 · eps -1.08 · loss
Beta-1.43vs S&P 500
Div yield0.00%annual · TTM
52w range
$3.27$21.73
Volume2.2Msession
| Revenue | $42.7M |
|---|---|
| Operating income | $-215.4M |
| Net income | $-204.4M |
| Free cash flow | $-188.2M |
| Operating margin | -504.1% |
| Net margin | -478.3% |
| Return on equity | -38.8% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-26
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 58.4%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -478.3%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -438.8%
- Accumulated Deficit High — Accumulated deficit / equity 252%
- Rd Intensity High — R&D/Revenue 427.8%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.32
Est. revenue
4.5M
Earnings transcripts
Press & signals
- GlobeNewswire
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
- GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
- GlobeNewswire
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans